Marketing Authorisation Application validated for cystic fibrosis treatment
The application was supported by positive results from two global Phase III studies in people with cystic fibrosis aged 12 and older.
List view / Grid view
The application was supported by positive results from two global Phase III studies in people with cystic fibrosis aged 12 and older.
A new agreement will allow eligible cystic fibrosis patients in England to have access to CFTR modulators to treat the underlying cause of their disease.
Campaigners call for UK Government to intervene on pricing dispute over cystic fibrosis drug Orkambi...